Mkts

Jazz Pharmaceuticals plc

NASDAQ: JAZZ
$243.54+8.79 (+3.74%)
As of Nov 9, 4:00 PM ET

Key statistics

Day range
235.14244.37
52-week range
128.80266.38
Today
Open237.10
Previous close243.54
Volume—
Valuation
Market cap15.45B
P/E ratio75.03×
EPS (TTM)3.07
Income & risk
Dividend / yield—
Beta0.34
Avg volume861.0K
Discussion

JAZZ News

Stories mentioning JAZZ from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue1,068,9001,197,9671,126,1071,045,712897,8001,088,1731,054,9691,023,825
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development
Sales General & Admin352,700406,225530,647358,399514,000369,287325,772338,523
Total Operating Expenses
Operating Income (Loss)336,600254,54357,509(686,392)(55,900)190,770260,210199,443
Interest Income23,40020,50018,60019,10027,60031,60026,00025,400
Interest Expense
Other Expense
Pretax Income
Tax Provision6,1004,951(242,424)(17,170)(17,800)(57,912)(14,533)(30,653)
Net Income (Loss)293,100203,410251,412(718,470)(92,500)191,115215,055168,568
Earnings Per Share (Basic)4.733.344.14(11.74)(1.52)3.093.502.68
Earnings Per Share (Diluted)4.433.344.08(11.74)(1.52)2.903.422.49
Weighted Average Shares Outstanding (Basic)61,90060,98160,69661,19461,00061,83861,41462,882
Weighted Average Shares Outstanding (Diluted)66,10060,98161,60661,19461,00066,00763,17469,625

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About JAZZ

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a stock listed on the Nasdaq Stock Market under the ticker symbol JAZZ. It last traded at $243.54 (Nov 9, 2026, 4:00 PM ET), up 3.7% on the day. That gives Jazz Pharmaceuticals a market capitalisation of $15.5B and a price-to-earnings ratio of 75.0.

Over the past 52 weeks JAZZ has traded between $128.80 and $266.38.

Revenue for the quarter ended Mar 31, 2026 was $1.1B; net income $293.1M. Revenue was up 19.1% from $897.8M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$1.1B$293.1M27.4%
Dec 31, 2025$1.2B$203.4M17.0%
Sep 30, 2025$1.1B$251.4M22.3%
Jun 30, 2025$1.0B-$718.5M-68.7%

From Jazz Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…